Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment
- Sub-Industry: N/A
- Symbol: NASDAQ:ENTL
- CUSIP: N/A
- Web: www.entellusmedical.com
Capitalization:- Market Cap: $438.41 million
- Outstanding Shares: 25,371,000
Average Prices:- 50 Day Moving Avg: $17.14
- 200 Day Moving Avg: $14.96
- 52 Week Range: $11.47 - $22.63
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -20.12
- P/E Growth: -0.31
Sales & Book Value:- Annual Revenue: $80.8 million
- Price / Sales: 5.43
- Book Value: $3.16 per share
- Price / Book: 5.47
Profitability:- EBIDTA: ($26,990,000.00)
- Net Margins: -41.11%
- Return on Equity: -60.34%
- Return on Assets: -36.76%
Debt:- Debt-to-Equity Ratio: 0.19%
- Current Ratio: 3.87%
- Quick Ratio: 3.53%
Misc:- Average Volume: 178,370 shs.
- Beta: 0.04
- Short Ratio: 12.52
Frequently Asked Questions for Entellus Medical (NASDAQ:ENTL)
What is Entellus Medical's stock symbol?
Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."
How were Entellus Medical's earnings last quarter?
Entellus Medical, Inc. (NASDAQ:ENTL) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.03. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The company's quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.27) earnings per share. View Entellus Medical's Earnings History.
When will Entellus Medical make its next earnings announcement?
Where is Entellus Medical's stock going? Where will Entellus Medical's stock price be in 2017?
7 equities research analysts have issued 12-month price targets for Entellus Medical's stock. Their forecasts range from $16.00 to $26.00. On average, they anticipate Entellus Medical's stock price to reach $22.00 in the next twelve months. View Analyst Ratings for Entellus Medical.
What are analysts saying about Entellus Medical stock?
Here are some recent quotes from research analysts about Entellus Medical stock:
- 1. According to Zacks Investment Research, "Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. " (8/1/2017)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted Entellus Medical’s management team for a day of investor meetings in Boston. We traveled with Bob White, President and CEO and Brent Moen, CFO. Meetings were largely positive as procedural growth (both office based and OR) and reimbursement changes remain a focus for investors. We came away from those meetings with a clearer understanding of reimbursement changes, broader product portfolio, and OUS growth potential. Net, net we remain positive about Entellus’ growth opportunities despite investor uncertainty on the reimbursement front headed into 2017. Near term, as management noted on the Q3/16 conference call, we expect Entellus will set conservative guidance for 2017 to the low end of the historic 20%-25% range, and as such, set the potential for a beat and raise cadence over the H2/17. We expect reimbursement will be at the forefront of investor minds moving into 2017 as the industry digests 30-50% cuts to reimbursement in the hospital outpatient setting." (12/20/2016)
Who are some of Entellus Medical's key competitors?
Some companies that are related to Entellus Medical include BeyondSpring (BYSI), Orthofix International N.V. (OFIX), Sangamo Therapeutics (SGMO), Eagle Pharmaceuticals (EGRX), Luminex Corporation (LMNX), Aduro Biotech (ADRO), Heron Therapeutics (HRTX), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Amarin Corporation PLC (AMRN), Arena Pharmaceuticals (ARNA), Keryx Biopharmaceuticals (KERX), Spectrum Pharmaceuticals (SPPI), Community Health Systems (CYH), Editas Medicine (EDIT), Cellectis S.A. (CLLS), Anika Therapeutics (ANIK) and AtriCure (ATRC).
Who are Entellus Medical's key executives?
Entellus Medical's management team includes the folowing people:
- Robert S. White, President, Chief Executive Officer, Director
- Brent A. Moen, Chief Financial Officer, Corporate Secretary
- Jonelle R. Burnham, Chief Compliance Officer, Vice President, General Counsel
- Stephen R. Paidosh, Vice President, Operations
- Thomas D. Williamson, Vice President - Sales
- Kevin L. Mensink, Vice President of Marketing
- Martha J. Christian, Vice President, Reimbursement
- Timothy B. Petrick, Vice President, Research and Development
- Brian E. Farley, Non-Executive Chairman of the Board
- James C. Momtazee, Director
When did Entellus Medical IPO?
(ENTL) raised $70 million in an initial public offering on Friday, January 30th 2015. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Who owns Entellus Medical stock?
Entellus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SV Health Investors LLC (13.49%),
KKR FUND HOLDINGS L.P.
(5.50%), Frontier Capital Management Co. LLC (3.95%), First Light Asset Management LLC (2.02%), Vanguard Group Inc. (2.21%) and Archon Capital Management LLC (1.89%). Company insiders that own Entellus Medical stock include Brent Moen, Brian E Farley, James D Surek, Joshua J Baltzell, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano, Robert S White and Timothy B Petrick. View Institutional Ownership Trends for Entellus Medical.
Who sold Entellus Medical stock? Who is selling Entellus Medical stock?
Entellus Medical's stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Federated Investors Inc. PA, Royce & Associates LP, Quinn Opportunity Partners LLC, Goldman Sachs Group Inc., Wells Fargo & Company MN and New York State Common Retirement Fund. Company insiders that have sold Entellus Medical stock in the last year include Brian E Farley, James D Surek, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International and Margaret A Boiano. View Insider Buying and Selling for Entellus Medical.
Who bought Entellus Medical stock? Who is buying Entellus Medical stock?
Entellus Medical's stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Tekla Capital Management LLC, Nicholas Company Inc., First Manhattan Co., Archon Capital Management LLC, First Light Asset Management LLC, Cypress Capital Management LLC WY and Vanguard Group Inc.. Company insiders that have bought Entellus Medical stock in the last two years include Brent Moen, Joshua J Baltzell and Robert S White. View Insider Buying and Selling for Entellus Medical.
How do I buy Entellus Medical stock?
Shares of Entellus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Entellus Medical's stock price today?
One share of Entellus Medical stock can currently be purchased for approximately $17.30.
MarketBeat Community Rating for Entellus Medical (NASDAQ ENTL)MarketBeat's community ratings are surveys of what our community members think about Entellus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Entellus Medical (NASDAQ:ENTL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.43) |
| Consensus Price Target: | $22.00 (27.17% upside) |
Analysts' Ratings History for Entellus Medical (NASDAQ:ENTL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/12/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | | Medium |  |
| 5/22/2017 | Canaccord Genuity | Set Price Target | Hold | $18.00 | Low | |
| 5/10/2017 | William Blair | Reiterated Rating | Outperform | | Low | |
| 2/22/2017 | Bank of America Corporation | Downgrade | Buy -> Underperform | $16.00 | N/A | |
| 2/22/2017 | BTIG Research | Downgrade | Buy -> Neutral | | N/A | |
| 12/6/2016 | Guggenheim | Initiated Coverage | Buy | $25.00 | N/A | |
| 11/4/2016 | Deutsche Bank AG | Reiterated Rating | Buy | $25.00 -> $26.00 | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for Entellus Medical (NASDAQ:ENTL)Earnings History by Quarter for Entellus Medical (NASDAQ ENTL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | | | | | | N/A | |
| 8/3/2017 | Q2 2017 | ($0.34) | ($0.37) | $21.87 million | $22.10 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.44) | ($0.40) | $19.61 million | $19.11 million | View | Listen | |
| 2/21/2017 | Q4 2016 | ($0.33) | ($0.39) | $21.58 million | $21.70 million | View | Listen | |
| 11/3/2016 | Q3 | ($0.37) | ($0.50) | $17.93 million | $17.90 million | View | Listen | |
| 8/3/2016 | Q2 | ($0.35) | ($0.27) | $18.48 million | $18.73 million | View | Listen | |
| 5/4/2016 | Q1 | ($0.47) | ($0.37) | $16.34 million | $16.90 million | View | Listen | |
| 2/24/2016 | Q4 | ($0.26) | ($0.27) | $17.52 million | $18.07 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.25) | ($0.32) | $14.19 million | $14.80 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.20) | ($0.15) | $15.00 million | $15.20 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Entellus Medical (NASDAQ:ENTL)2017 EPS Consensus Estimate: ($1.35)
2018 EPS Consensus Estimate: ($0.94)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.38) | ($0.38) | ($0.38) |
| Q2 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q3 2017 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q4 2017 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q1 2018 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q2 2018 | 1 | ($0.22) | ($0.22) | ($0.22) |
| Q3 2018 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q4 2018 | 1 | ($0.13) | ($0.13) | ($0.13) |
(Data provided by Zacks Investment Research)
Dividend History for Entellus Medical (NASDAQ:ENTL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Entellus Medical (NASDAQ:ENTL)Insider Ownership Percentage: 9.10%
Institutional Ownership Percentage: 67.61%
Insider Trades by Quarter for Entellus Medical (NASDAQ:ENTL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/8/2017 | Brent Moen | CFO | Buy | 6,100 | $12.21 | $74,481.00 | |
| 5/8/2017 | Joshua J Baltzell | Director | Buy | 1,600 | $12.34 | $19,744.00 | |
| 5/8/2017 | Robert S. White | Insider | Buy | 10,000 | $12.24 | $122,400.00 | |
| 1/31/2017 | Life Sciences Fu International | Major Shareholder | Sell | 533,077 | $17.00 | $9,062,309.00 | |
| 1/13/2017 | Brian E Farley | Director | Sell | 14,019 | $20.14 | $282,342.66 | |
| 1/13/2017 | Karen E. Peterson | VP | Sell | 10,000 | $20.13 | $201,300.00 | |
| 1/10/2017 | Brian E Farley | Director | Sell | 9,842 | $19.11 | $188,080.62 | |
| 1/10/2017 | Karen E. Peterson | VP | Sell | 9,840 | $19.11 | $188,042.40 | |
| 1/4/2017 | Brian E Farley | Director | Sell | 20,158 | $18.74 | $377,760.92 | |
| 1/4/2017 | Karen E Peterson | VP | Sell | 10,160 | $18.74 | $190,398.40 | |
| 12/6/2016 | Brian E Farley | Director | Sell | 15,000 | $18.57 | $278,550.00 | |
| 11/23/2016 | Brian E Farley | Director | Sell | 5,000 | $19.00 | $95,000.00 | |
| 11/18/2016 | Brian E Farley | Director | Sell | 10,000 | $18.30 | $183,000.00 | |
| 10/13/2016 | Margaret A. Boiano | VP | Sell | 11,103 | $20.01 | $222,171.03 | |
| 10/5/2016 | Brian E Farley | Director | Sell | 30,000 | $22.26 | $667,800.00 | |
| 9/8/2016 | James D Surek | VP | Sell | 10,000 | $18.71 | $187,100.00 | |
| 9/2/2016 | Brian E Farley | Director | Sell | 11,078 | $18.62 | $206,272.36 | |
| 9/1/2016 | Brian E Farley | Director | Sell | 17,006 | $19.33 | $328,725.98 | |
| 9/1/2016 | Kevin L. Mensink | VP | Sell | 8,000 | $18.39 | $147,120.00 | |
| 8/1/2016 | Kevin L Mensink | VP | Sell | 8,100 | $17.63 | $142,803.00 | |
| 7/18/2016 | Timothy B. Petrick | VP | Sell | 3,000 | $18.15 | $54,450.00 | |
| 2/11/2016 | Karen E Peterson | Insider | Sell | 5,000 | $16.00 | $80,000.00 | |
| 2/4/2016 | Karen E Peterson | Insider | Sell | 10,000 | $17.00 | $170,000.00 | |
| 9/17/2015 | Brian E. Farley | Chairman | Sell | 5,484 | $22.00 | $120,648.00 | |
| 9/15/2015 | Brian E. Farley | Chairman | Sell | 27,619 | $22.18 | $612,589.42 | |
| 9/14/2015 | Brian E. Farley | Chairman | Sell | 21,187 | $22.15 | $469,292.05 | |
| 9/2/2015 | James D Surek | VP | Sell | 15,000 | $21.27 | $319,050.00 | |
| 8/31/2015 | James D. Surek | VP | Sell | 5,000 | $22.29 | $111,450.00 | |
| 2/3/2015 | Robert S White | COO | Buy | 5,882 | $17.00 | $99,994.00 | |
| 2/3/2015 | Shawn Mccormick | Director | Buy | 2,941 | $17.00 | $49,997.00 | |
| 2/3/2015 | Woodlands Health Venture Essex | Major Shareholder | Buy | 352,941 | $17.00 | $5,999,997.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Entellus Medical (NASDAQ:ENTL)
Latest Headlines for Entellus Medical (NASDAQ:ENTL)
| Source: |
|
| Date | Headline |
|---|
 | Entellus Medical, Inc. (ENTL) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 15 at 6:50 AM |
 | Entellus Medical Announces New Employee Inducement Option Grants
finance.yahoo.com - August 8 at 6:05 PM |
| Zacks: Brokerages Anticipate Entellus Medical, Inc. (NASDAQ:ENTL) Will Post Quarterly Sales of $21.03 Million
www.americanbankingnews.com - August 8 at 7:34 AM |
| Critical Contrast: Tactile Systems Technology (TCMD) versus Entellus Medical (NASDAQ:ENTL)
www.americanbankingnews.com - August 6 at 8:22 PM |
| Entellus Medical, Inc. (ENTL) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - August 6 at 6:08 PM |
 | Entellus Medical's (ENTL) CEO Bob White on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 5 at 5:29 PM |
| Entellus Medical, Inc. (NASDAQ:ENTL) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 4 at 11:08 PM |
| Edited Transcript of ENTL earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 6:33 PM |
| Entellus reports 2Q loss
finance.yahoo.com - August 3 at 9:59 PM |
| Entellus Medical Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 4:59 PM |
| Contrasting Tactile Systems Technology (TCMD) & Entellus Medical (ENTL)
www.americanbankingnews.com - August 3 at 2:38 PM |
| Entellus Medical, Inc. (NASDAQ:ENTL) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - August 1 at 5:56 PM |
| Analyzing Entellus Medical (NASDAQ:ENTL) and Masimo Corporation (MASI)
www.americanbankingnews.com - July 31 at 9:33 AM |
| Entellus Medical to Present at the Canaccord Genuity Annual Growth Conference
finance.yahoo.com - July 26 at 6:51 PM |
| Critical Contrast: Entellus Medical (ENTL) vs. Penumbra (PEN)
www.americanbankingnews.com - July 22 at 2:15 PM |
| Entellus Medical, Inc. (ENTL) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 21 at 7:40 AM |
| Entellus Medical to Report Second Quarter 2017 Financial Results August 3, 2017
finance.yahoo.com - July 20 at 9:04 PM |
| Entellus Medical, Inc. (NASDAQ:ENTL) Expected to Announce Quarterly Sales of $21.17 Million
www.americanbankingnews.com - July 19 at 1:28 PM |
| Brokerages Expect Entellus Medical, Inc. (NASDAQ:ENTL) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - July 17 at 2:28 PM |
| Entellus Medical (NASDAQ:ENTL) versus Penumbra (PEN) Head to Head Review
www.americanbankingnews.com - July 17 at 9:55 AM |
| Entellus Medical Inc (NASDAQ:ENTL) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - July 16 at 11:06 AM |
| Reviewing Penumbra (PEN) & Entellus Medical (NASDAQ:ENTL)
www.americanbankingnews.com - July 13 at 6:40 PM |
| Entellus Medical, Inc. (ENTL) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - July 12 at 7:56 AM |
| Entellus Medical, Inc. (NASDAQ:ENTL) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - July 12 at 12:44 AM |
| Entellus Medical, Inc. (NASDAQ:ENTL) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - July 8 at 7:08 PM |
 | BRIEF-Entellus Medical to acquire Spirox Inc
www.reuters.com - July 8 at 5:52 PM |
 | Entellus Medical (ENTL) to Acquire Spirox for $25M Cash, 3.4M Shares
www.streetinsider.com - July 8 at 5:52 PM |
| Entellus Medical Announces Definitive Agreement to Acquire Spirox
finance.yahoo.com - July 8 at 10:30 AM |
| [$$] Entellus Medical Agrees to Acquire KKR-Backed Spirox
finance.yahoo.com - July 8 at 10:30 AM |
| Entellus Medical, Inc. (ENTL) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 5 at 6:50 PM |
| ETFs with exposure to Entellus Medical, Inc. : July 3, 2017
finance.yahoo.com - July 3 at 6:09 PM |
| Entellus Medical, Inc. (ENTL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - June 26 at 8:02 AM |
| Analysts Expect Entellus Medical, Inc. (ENTL) Will Post Quarterly Sales of $21.17 Million
www.americanbankingnews.com - June 23 at 4:00 PM |
| Zacks: Analysts Anticipate Entellus Medical, Inc. (ENTL) to Announce -$0.34 EPS
www.americanbankingnews.com - June 21 at 12:08 PM |
| ETFs with exposure to Entellus Medical, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 7:37 PM |
| ETFs with exposure to Entellus Medical, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 5:59 PM |
| Entellus Medical, Inc. :ENTL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 5:24 PM |
| Entellus Medical Inc (ENTL) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 6:46 PM |
| Entellus Medical to Present at the William Blair Growth Stock Conference
finance.yahoo.com - June 1 at 5:45 PM |
| Entellus Medical Inc (ENTL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 30 at 8:00 AM |
| $21.17 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - May 28 at 9:54 AM |
| -$0.34 Earnings Per Share Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - May 26 at 8:54 AM |
| Canaccord Genuity Analysts Give Entellus Medical Inc (ENTL) a $18.00 Price Target
www.americanbankingnews.com - May 23 at 9:20 PM |
| Entellus Medical Inc (ENTL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 23 at 5:04 PM |
| The Centers for Medicare & Medicaid Services (CMS) Establishes Coding and Payment for Eustachian Tube Balloon Dilation
finance.yahoo.com - May 22 at 4:43 PM |
| Q2 2017 Earnings Estimate for Entellus Medical Inc Issued By William Blair (ENTL)
www.americanbankingnews.com - May 12 at 10:20 AM |
| Q2 2018 Earnings Forecast for Entellus Medical Inc Issued By William Blair (ENTL)
www.americanbankingnews.com - May 11 at 2:14 PM |
| Entellus Medical Inc (ENTL) Earns "Outperform" Rating from William Blair
www.americanbankingnews.com - May 10 at 3:26 PM |
| Entellus Medical Inc (ENTL) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:38 PM |
| Entellus Medical Inc (ENTL) Director Buys $19,744.00 in Stock
www.americanbankingnews.com - May 8 at 10:08 PM |
Entellus Medical (ENTL) Chart for Saturday, August, 19, 2017
